跳至主要内容
临床试验/JPRN-UMIN000003907
JPRN-UMIN000003907已完成未知

A pilot study of the generic drug of Tamsulosin Hydrochloride to evaluate the efficacy for benign prostatic hyperplasia patients with dysuria. - A pilot study of generic Tamsulosin for benign prostatic hyperplasia patients with dysuria.

PO MINS0 个研究点目标入组 20 人开始时间: 2010年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

简要总结

The I-PSS and the QOL score were significantly decreased after 4 weeks dosing of Restream®. And the safety profile was similar to that of the original drug. These results confirmed that 4 weeks treatment by the generic drug of Tamsulosin Hydrochloride, Restream®OD tablet, would be effective and be safety for BPH with moderate to severe dysuria.

研究设计

研究类型
Interventional

入排标准

年龄范围
50years-old 至 90years-old(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1) Patients who treated by medicine that has androgenic hormone within 4 weeks before IC. 2) Patients with cases or suspicion of prostatic cancer 3) Patients with suspicion of neurogenic bladder 4) Patients with urethral stricture 5) Patients with chronic bacterial prostatitis or active urinary tract infection 6) Past history of surgery or invasive therapy for BPH. 7) Irradiation for pelvic area within 1 year prior to IC. 8) Patients with any disease that induce dysuria (such as bladder neck contracture or urolithiasis) 9) Patients with cardiovascular disease. 10) Patients with serious disease or impairment of liver, kidney and blood 11) patients who are participated in any clinical studies within 3 months prior to the study 12) Patients who are judged inappropriate for the clinical trial by the investigator

研究者

发起方
PO MINS

相似试验